Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Eltanexor |
Synonyms | |
Therapy Description |
Eltanexor (KPT-8602) inhibits exportin-1 (XPO1), resulting in decreased nuclear export and potentially resulting in increased tumor cell death (PMID: 27780859). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Eltanexor | KPT-8602 | Eltanexor (KPT-8602) inhibits exportin-1 (XPO1), resulting in decreased nuclear export and potentially resulting in increased tumor cell death (PMID: 27780859). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TET2 del | acute myeloid leukemia | sensitive | Eltanexor | Preclinical - Cell culture | Actionable | In a preclinical study, Eltanexor (KPT-8602) induced apoptosis in TET2-knockout acute myeloid leukemia cell lines, resulting in decreased cell viability in culture (PMID: 36746437). | 36746437 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02649790 | Phase Ib/II | Eltanexor | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | FRA | ESP | CAN | 1 |